[A study of the efficacy and safety of a new modified-release betahistine formulation in the treatment of vestibular vertigo and Meniere's disease].

V A Parfenov M V Zamergrad D V Kazei Jos Nauta

Published in: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2021)

Betahistine MR (48 mg once daily) is non-inferior to betaserc (24 mg twice daily) in patients with Meniere's disease or vestibular vertigo and has a comparable safety profile.

Keyphrases

physical activity
drug delivery
magnetic resonance
magnetic resonance imaging
hearing loss
computed tomography
contrast enhanced
replacement therapy
smoking cessation